Nancy L Bartlett Selected Research

Antigens

1/2021	CAR-T therapy in solid organ transplant recipients with treatment refractory posttransplant lymphoproliferative disorder.
1/2020	Hodgkin lymphoma.
1/2016	Expression of TIA1 and PAX5 in Classical Hodgkin Lymphoma at Initial Diagnosis May Predict Clinical Outcome.
4/2009	Drug development for recurrent and refractory classical Hodgkin lymphoma.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Nancy L Bartlett Research Topics

Disease

63	Hodgkin Disease (Hodgkin's Disease) 01/2022 - 02/2002
43	Neoplasms (Cancer) 06/2022 - 05/2002
39	Lymphoma (Lymphomas) 07/2022 - 08/2003
22	Diffuse Large B-Cell Lymphoma (Lymphoma, Large Cell, Diffuse) 06/2022 - 08/2003
20	Follicular Lymphoma (Lymphoma, Small Cleaved Cell, Follicular) 01/2022 - 06/2002
18	B-Cell Lymphoma (Lymphoma, B Cell) 11/2021 - 08/2003
16	Non-Hodgkin Lymphoma (Lymphosarcoma) 11/2021 - 05/2002
13	Leukemia 11/2020 - 07/2007
11	Neutropenia 01/2022 - 05/2014
11	Anaplastic Large-Cell Lymphoma (Ki 1 Lymphoma) 10/2018 - 07/2009
10	Mantle-Cell Lymphoma (Lymphoma, Mantle Cell) 10/2020 - 02/2008
6	Disease Progression 12/2020 - 11/2011
6	Fatigue 06/2020 - 06/2012
6	Hematologic Neoplasms (Hematological Malignancy) 01/2019 - 02/2008
5	B-Cell Chronic Lymphocytic Leukemia (Chronic Lymphocytic Leukemia) 12/2020 - 12/2015
5	Exanthema (Rash) 01/2020 - 11/2002
5	Peripheral T-Cell Lymphoma (Lymphoma, T Cell, Peripheral) 01/2019 - 01/2012
4	Febrile Neutropenia 01/2022 - 01/2017
4	Peripheral Nervous System Diseases (PNS Diseases) 12/2017 - 09/2012
4	Thrombocytopenia (Thrombopenia) 01/2017 - 06/2002
3	Nausea 12/2021 - 12/2015
3	Infections 10/2021 - 01/2015
3	Cytokine Release Syndrome 01/2021 - 01/2017
3	Body Weight (Weight, Body) 11/2018 - 11/2010
2	Second Primary Neoplasms (Neoplasms, Second) 01/2022 - 10/2019
2	Pancreatitis 01/2021 - 11/2020
2	Cardiovascular Diseases (Cardiovascular Disease) 12/2020 - 01/2018
2	Multiple Myeloma 12/2020 - 02/2008
2	Burkitt Lymphoma (Burkitt's Lymphoma) 01/2020 - 02/2014
2	Vomiting 10/2019 - 12/2015
2	Diarrhea 10/2019 - 12/2015
2	Bites and Stings (Sting) 06/2019 - 05/2015
2	Progressive Multifocal Leukoencephalopathy 01/2019 - 11/2012
2	Precursor Cell Lymphoblastic Leukemia-Lymphoma (Acute Lymphoblastic Leukemia) 01/2018 - 05/2015
2	Cough 12/2015 - 01/2015
2	Anemia 12/2015 - 06/2012
2	T-Cell Lymphoma (Lymphoma, T Cell) 07/2015 - 05/2014
2	Mycosis Fungoides 07/2015 - 05/2012
2	Cytopenia 01/2015 - 11/2011

Drug/Important Bio-Agent (IBA)

34	Brentuximab VedotinIBA 01/2022 - 07/2008
32	Rituximab (Mabthera)FDA Link 11/2021 - 05/2002
25	Doxorubicin (Adriamycin)FDA LinkGeneric 01/2022 - 08/2006
13	Vinblastine (Vinblastine Sulfate)FDA Link 01/2022 - 07/2008
13	Dacarbazine (DIC)FDA LinkGeneric 01/2022 - 07/2008
12	Bleomycin (Blenoxane)FDA LinkGeneric 01/2022 - 07/2008
12	Prednisone (Sone)FDA LinkGeneric 11/2021 - 04/2013
12	Cyclophosphamide (Cytoxan)FDA LinkGeneric 11/2021 - 06/2014
11	ibrutinibIBA 01/2022 - 12/2015
11	Vincristine (Oncovin)FDA LinkGeneric 11/2021 - 04/2013
11	Monoclonal AntibodiesIBA 01/2021 - 08/2003
11	Lenalidomide (CC 5013)FDA Link 12/2020 - 02/2008
10	Immunoconjugates (Immunoconjugate)IBA 01/2022 - 04/2009
8	Etoposide (VP 16)FDA LinkGeneric 11/2021 - 04/2013
7	Bendamustine Hydrochloride FDA Link 12/2020 - 01/2010
6	NivolumabIBA 12/2021 - 12/2017
5	Biomarkers (Surrogate Marker)IBA 06/2022 - 01/2017
5	axicabtagene ciloleucelIBA 01/2021 - 01/2017
5	Bortezomib (Velcade)FDA Link 01/2020 - 07/2007
5	Pharmaceutical PreparationsIBA 01/2019 - 04/2009
4	Granulocyte Colony-Stimulating Factor (G-CSF)IBA 01/2022 - 10/2016
4	pembrolizumabIBA 01/2022 - 12/2017
4	Proteins (Proteins, Gene)FDA Link 11/2021 - 06/2008
4	Chimeric Antigen ReceptorsIBA 01/2021 - 12/2017
4	AntigensIBA 01/2021 - 04/2009
3	AnthracyclinesIBA 12/2020 - 05/2015
3	Biological ProductsIBA 04/2017 - 05/2002
3	Histone Deacetylase InhibitorsIBA 03/2016 - 07/2008
3	Gemcitabine FDA Link 05/2011 - 11/2002
3	ibritumomab tiuxetan (Zevalin)FDA Link 04/2003 - 05/2002
2	Adrenal Cortex Hormones (Corticosteroids)IBA 12/2021 - 01/2021
2	ALT-803IBA 01/2021 - 02/2016
2	polatuzumab vedotinIBA 01/2021 - 01/2019
2	Interleukin-15 (Interleukin 15)IBA 01/2021 - 11/2020
2	CytokinesIBA 11/2020 - 01/2019
2	CreatinineIBA 11/2020 - 06/2014
2	ofatumumab FDA Link 10/2019 - 01/2019
2	Immune Checkpoint InhibitorsIBA 01/2019 - 11/2018
2	L-Lactate Dehydrogenase (Lactate Dehydrogenase)IBA 01/2019 - 08/2015
2	Agammaglobulinaemia Tyrosine KinaseIBA 11/2018 - 02/2016
2	Chlorambucil (Leukeran)FDA Link 01/2018 - 12/2015
2	blinatumomabIBA 01/2018 - 05/2015
2	Fluorodeoxyglucose F18 (Fludeoxyglucose F 18)FDA Link 10/2016 - 03/2011
2	Methotrexate (Mexate)FDA LinkGeneric 10/2016 - 06/2014
2	Mechlorethamine (Nitrogen Mustard)FDA Link 06/2015 - 04/2013
2	dacetuzumabIBA 01/2015 - 06/2014
2	ParaffinIBA 02/2013 - 10/2012
2	Formaldehyde (Formol)FDA Link 02/2013 - 10/2012
2	Surface Antigens (Surface Antigen)IBA 09/2012 - 04/2009
2	AntibodiesIBA 07/2010 - 08/2003

Therapy/Procedure

57	Therapeutics 07/2022 - 06/2002
38	Drug Therapy (Chemotherapy) 10/2021 - 02/2002
13	Immunotherapy 01/2021 - 05/2002
9	Radiotherapy 10/2020 - 02/2002
8	Stem Cell Transplantation 01/2020 - 12/2009
4	Salvage Therapy 12/2021 - 08/2003
4	Combination Drug Therapy (Combination Chemotherapy) 10/2016 - 08/2003
4	Radioimmunotherapy 04/2009 - 05/2002
2	Injections 01/2022 - 10/2018
2	Aftercare (After-Treatment) 10/2019 - 05/2011
2	Retreatment 03/2014 - 03/2012